CLRB Phase 2 readout: a positive outcome, +6.7%

On December 22, 2025, Iopofosine I 131 single dose — Cellectar Biosciences, Inc. (Waldenstrom Macroglobulinemia) reached its Phase 2 readout. The result was a positive outcome, and the stock moved +6.7% in the window around the event. It had already run -6.3% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.